{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:58:25Z","timestamp":1775289505462,"version":"3.50.1"},"reference-count":65,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences of the National Institutes of Health","doi-asserted-by":"publisher","award":["TL1TR000422"],"award-info":[{"award-number":["TL1TR000422"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA032507"],"award-info":[{"award-number":["DA032507"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["DML"],"published-print":{"date-parts":[[2019,4,30]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>&lt;P&gt;Background: Bupropion (BUP) is widely used as an antidepressant and smoking cessation aid. There are three major pharmacologically active metabolites of BUP, Erythrohydrobupropion (EB), Hydroxybupropion (OHB) and Threohydrobupropion (TB). At present, the mechanisms underlying the overall disposition and systemic clearance of BUP and its metabolites have not been well understood, and the role of transporters has not been studied. &lt;\/P&gt;&lt;P&gt; Objective: The goal of this study was to investigate whether BUP and its active metabolites are substrates of the major hepatic uptake and efflux transporters. &lt;\/P&gt;&lt;P&gt; Method: CHO or HEK293 cell lines or plasma membrane vesicles that overexpress OATP1B1, OATP1B3, OATP2B1, OATP4A1, OCT1, BCRP, MRP2 or P-gp were used in cellular or vesicle uptake and inhibition assays. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS\/MS) was used to quantify transport activity. &lt;\/P&gt;&lt;P&gt; Results: BUP and its major active metabolites were actively transported into the CHO or HEK293 cells overexpressing OATP1B1, OATP1B3 or OATP2B1; however, such cellular active uptake could not be inhibited at all by prototypical inhibitors of any of the OATP transporters. These compounds were not transported by OCT1, BCRP, MRP2 or P-gp either. These results suggest that the major known hepatic transporters likely play a minor role in the overall disposition and systemic clearance of BUP and its active metabolites in humans. We also demonstrated that BUP and its metabolites were not transported by OATP4A1, an uptake transporter on the apical membrane of placental syncytiotrophoblasts, suggesting that OATP4A1 is not responsible for the transfer of BUP and its metabolites from the maternal blood to the fetal compartment across the placental barrier in pregnant women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>BUP and metabolites are not substrates of the major hepatic transporters tested and thus these hepatic transporters likely do not play a role in the overall disposition of the drug. Our results also suggest that caution should be taken when using the model CHO and HEK293 cell lines to evaluate potential roles of transporters in drug disposition.&lt;\/P&gt;<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1872312813666181129101507","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T06:27:40Z","timestamp":1543472860000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines"],"prefix":"10.2174","volume":"13","author":[{"given":"Lyrialle W.","family":"Han","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunying","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingcheng","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(24)38905-0","volume":"295","author":"Slemmer J.E.","year":"2000","unstructured":"Slemmer JE, Martin BR, Damaj MI. J Pharmacol Exp Ther, bupropion is a nicotinic antagonist.,, 2000, 295,, 321-327,","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-3565(25)32266-4","volume":"215","author":"Cooper B.R.","year":"1980","unstructured":"Cooper BR, Hester TJ, Maxwell RA. J Pharmacol Exp Ther, Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo.,, 1980, 215,, 127-134,","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=3","first-page":"74","volume":"44","author":"Ferris R.M.","year":"1983","unstructured":"Ferris RM, Cooper BR, Maxwell RA. J Clin Psychiatry, Studies of bupropion\u2019s mechanism of antidepressant activity.,, 1983, 44,, 74-78,","journal-title":"J Clin Psychiatry"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/oby.2001.71","volume":"9","author":"Gadde K.M.","year":"2001","unstructured":"Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, Krishnan KRR. Obes Res, Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women.,, 2001, 9,, 544-551,","journal-title":"Obes Res"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2133\/dmpk.DMPK-13-RG-051","volume":"29","author":"Skarydova L.","year":"2014","unstructured":"Skarydova L, Tomanova R, Havlikova L, Stambergova H, Solich P, Wsol V. Drug Metab Pharmacokinet, Deeper insight into the reducing biotransformation of bupropion in the human liver.,, 2014, 29,, 177-184,","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"e3165","DOI":"10.1097\/MD.0000000000003165","volume":"95","author":"Li D-J.","year":"2016","unstructured":"Li D-J, Tseng P-T, Chen Y-W, Wu C-K, Lin P-Y. Medicine, Significant treatment effect of bupropion in patients with bipolar disorder but similar phase-shifting rate as other antidepressants.,, 2016, 95,, e3165-,","journal-title":"Medicine"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/cap.2016.0124","volume":"27","author":"Ng Q.X.","year":"2016","unstructured":"Ng QX. J Child Adolesc Psychopharmacol, A systematic review of the use of bupropion for attention-deficit\/hyperactivity disorder in children and adolescents.,, 2016, 27,, 112-116,","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=8","first-page":"CD009504","volume":"10","author":"Verbeeck W.","year":"2017","unstructured":"Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Cochrane Database Syst Rev, Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults.,, 2017, 10,, CD009504-,","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00637513","volume":"21","author":"Findlay J.W.A.","year":"1981","unstructured":"Findlay JWA, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML, Blum MR, Schroeder DH. Eur J Clin Pharmacol, Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects.,, 1981, 21,, 127-135,","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FPC.0b013e32835d9ab0","volume":"23","author":"Benowitz N.L.","year":"2013","unstructured":"Benowitz NL, Zhu AZX, Tyndale RF, Dempsey D, Jacob P. Pharmacogenet Genomics, III. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.,, 2013, 23,, 135-141,","journal-title":"Pharmacogenet Genomics"},{"key":"ref=11","first-page":"79","volume":"44","author":"Schroeder D.H.","year":"1983","unstructured":"Schroeder DH. J Clin Psychiatry, Metabolism and kinetics of bupropion.,, 1983, 44,, 79-81,","journal-title":"J Clin Psychiatry"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.bcp.2010.01.026","volume":"79","author":"Wang X.","year":"2010","unstructured":"Wang X, Abdelrahman DR, Zharikova OL, Patrikeeva SL, Hankins GDV, Ahmed MS, Nanovskaya TN. Biochem Pharmacol, Bupropion metabolism by human placenta.,, 2010, 79,, 1684-1690,","journal-title":"Biochem Pharmacol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1124\/dmd.113.052936","volume":"41","author":"Meyer A.","year":"2013","unstructured":"Meyer A, Vuorinen A, Zielinska AE, Strajhar P, Lavery GG, Schuster D, Odermatt A. Drug Metab Dispos, Formation of threohydrobupropion from bupropion is dependent on 11\u03b2-Hydroxysteroid dehydrogenase 1.,, 2013, 41,, 1671-1678,","journal-title":"Drug Metab Dispos"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0014-2999(03)02010-7","volume":"474","author":"Bondarev M.L.","year":"2003","unstructured":"Bondarev ML, Bondareva TS, Young R, Glennon RA. Eur J Pharmacol, Behavioral and biochemical investigations of bupropion metabolites.,, 2003, 474,, 85-93,","journal-title":"Eur J Pharmacol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.clinthera.2005.11.011","volume":"27","author":"Jefferson J.W.","year":"2005","unstructured":"Jefferson JW, Pradko JF, Muir KT. Clin Ther, Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.,, 2005, 27,, 1685-1695,","journal-title":"Clin Ther"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/jpet.116.232876","volume":"358","author":"Masters A.R.","year":"2016","unstructured":"Masters AR, Gufford BT, Lu JBL, Metzger IF, Jones DR, Desta Z. J Pharmacol Exp Ther, Chiral plasma pharmacokinetics and urinary excretion of bupropion and metabolites in healthy volunteers.,, 2016, 358,, 230-238,","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"497e1","DOI":"10.1016\/j.ajog.2016.05.016","volume":"215","author":"Fokina V.M.","year":"2016","unstructured":"Fokina VM, West H, Oncken C, Clark SM, Ahmed MS, Hankins GD, Nanovskaya TN. Am. J. Obstet. Gynecol., , Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid., , 2016","journal-title":"Am J Obstet Gynecol,"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1124\/dmd.116.072363","volume":"44","author":"Sager J.E.","year":"2016","unstructured":"Sager JE, Price LSL, Isoherranen N. Drug Metab Dispos, Stereoselective metabolism of bupropion to OH-Bupropion, threohydrobupropion, erythrohydrobupropion and 4\u2032-OH-Bupropion in vitro.,, 2016, 44,, 1709-1719,","journal-title":"Drug Metab Dispos"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","volume":"165","author":"Roth M.","year":"2012","unstructured":"Roth M, Obaidat A, Hagenbuch B. Br J Pharmacol, OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.,, 2012, 165,, 1260-1287,","journal-title":"Br J Pharmacol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00404-011-2183-4","volume":"285","author":"Wang H.","year":"2012","unstructured":"Wang H, Yan Z, Dong M, Zhu X, Wang H, Wang Z. Arch Gynecol Obstet, Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy.,, 2012, 285,, 1535-1540,","journal-title":"Arch Gynecol Obstet"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/gast.2001.21176","volume":"120","author":"Kullak-Ublick G.A.","year":"2001","unstructured":"Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. Gastroenterology, Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.,, 2001, 120,, 525-533,","journal-title":"Gastroenterology"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/00498250801986951","volume":"38","author":"Hagenbuch B.","year":"2008","unstructured":"Hagenbuch B, Gui C. Xenobiotica, Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family.,, 2008, 38,, 778-801,","journal-title":"Xenobiotica"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.439","volume":"100","author":"Ronaldson P.","year":"2016","unstructured":"Ronaldson P, Bauer B, El-Kattan A, Shen H, Salphati L, Louie S. Clin Pharmacol Ther, Highlights from the american association of pharmaceutical scientists\/ international transporter consortium joint workshop on drug transporters in absorption, distribution, metabolism, and excretion: From the bench to the bedside - Clinical pharmacology C.,, 2016, 100,, 419-422,","journal-title":"Clin Pharmacol Ther"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/9781118705308.ch17","author":"Mao Q.","year":"2014","unstructured":"Mao Q, Ganapathy V, Unadkat JD. In Drug Transporters., , John Wiley and Sons, Inc.: Hoboken,NJ,, 2014","journal-title":"In Drug Transporters"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clpt.2005.02.010","volume":"77","author":"Turpeinen M.","year":"2005","unstructured":"Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Clin Pharmacol Ther, Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.,, 2005, 77,, 553-559,","journal-title":"Clin Pharmacol Ther"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/FPC.0b013e3283620c3b","volume":"23","author":"Tamraz B.","year":"2013","unstructured":"Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR. Pharmacogenet Genomics, OATP1B1-Related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.,, 2013, 23,, 355-364,","journal-title":"Pharmacogenet Genomics"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4292\/wjgpt.v8.i1.26","volume":"8","author":"Telles-Correia D.","year":"2017","unstructured":"Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NBF, Machado S. World J Gastrointest Pharmacol Ther, Psychotropic drugs and liver disease: a critical review of pharmacokinetics and liver toxicity.,, 2017, 8,, 26-38,","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tox.2017.06.004","volume":"387","author":"Luethi D.","year":"2017","unstructured":"Luethi D, Liechti ME, Kr\u00e4henb\u00fchl S. Toxicology, Mechanisms of hepatocellular toxicity associated with new psychoactive synthetic cathinones.,, 2017, 387,, 57-66,","journal-title":"Toxicology"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/clpt.2012.79","volume":"92","author":"K\u00f6ck K.","year":"2012","unstructured":"K\u00f6ck K, Brouwer KLR. Clin Pharmacol Ther, A perspective on efflux transport proteins in the liver.,, 2012, 92,, 599-612,","journal-title":"Clin Pharmacol Ther"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","volume":"20","author":"Choi Y.H.","year":"2014","unstructured":"Choi YH, Yu A-M. Curr Pharm Des, ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.,, 2014, 20,, 793-807,","journal-title":"Curr Pharm Des"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1007\/s11095-016-2028-8","volume":"33","author":"Joshi A.A.","year":"2016","unstructured":"Joshi AA, Vaidya SS, St-Pierre MV, Mikheev AM, Desino KE, Nyandege AN, Audus KL, Unadkat JD, Gerk PM. Pharm Res, Placental ABC transporters: Biological impact and pharmaceutical significance.,, 2016, 33,, 2847-2878,","journal-title":"Pharm Res"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1124\/dmd.111.038166","volume":"39","author":"Mason C.W.","year":"2011","unstructured":"Mason CW, Buhimschi IA, Buhimschi CS, Dong Y, Weiner CP, Swaan PW. Drug Metab Dispos, ATP-binding cassette transporter expression in human placenta as a function of pregnancy condition.,, 2011, 39,, 1000-1007,","journal-title":"Drug Metab Dispos"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/138920111795164057","volume":"12","author":"Ni Z.","year":"2011","unstructured":"Ni Z, Mao Q. Curr Pharm Biotechnol, ATP-binding cassette efflux transporters in human placenta.,, 2011, 12,, 674-685,","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s11095-008-9537-z","volume":"25","author":"Mao Q.","year":"2008","unstructured":"Mao Q. Pharm Res, BCRP\/ABCG2 in the placenta: Expression, function and regulation.,, 2008, 25,, 1244-1255,","journal-title":"Pharm Res"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2174\/1381612043384844","volume":"10","author":"Begley D.J.","year":"2004","unstructured":"Begley DJ. Curr Pharm Des, ABC transporters and the blood-brain barrier.,, 2004, 10,, 1295-1312,","journal-title":"Curr Pharm Des"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpt.64","volume":"97","author":"Miller D.","year":"2015","unstructured":"Miller D. Clin Pharmacol Ther, Regulation of ABC transporters at the blood-brain barrier.,, 2015, 97,, 395-403,","journal-title":"Clin Pharmacol Ther"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1517\/17425255.2016.1168804","volume":"12","author":"Mahringer A.","year":"2016","unstructured":"Mahringer A, Fricker G. Expert Opin Drug Metab Toxicol, ABC transporters at the blood-brain barrier.,, 2016, 12,, 499-508,","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00253-011-3806-1","volume":"94","author":"Beckmann T.F.","year":"2012","unstructured":"Beckmann TF, Kr\u00e4mer O, Klausing S, Heinrich C, Th\u00fcte T, B\u00fcntemeyer H, Hoffrogge R, Noll T. Appl Microbiol Biotechnol, Effects of high passage cultivation on CHO cells: A global analysis.,, 2012, 94,, 659-671,","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/dmd.117.078881","volume":"46","author":"Gao C.","year":"2018","unstructured":"Gao C, Liao MZ, Han LW, Thummel KE, Mao Q. Drug Metab Dispos, Hepatic transport of 25-Hydroxyvitamin D3 conjugates: A mechanism of 25-Hydroxyvitamin D3 delivery to the intestinal tract.,, 2018, 46,, 581-591,","journal-title":"Drug Metab Dispos"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bcp.2011.04.014","volume":"82","author":"Wang X.","year":"2011","unstructured":"Wang X, Abdelrahman DR, Fokina VM, Hankins GDV, Ahmed MS, Nanovskaya TN. Biochem Pharmacol, Metabolism of bupropion by baboon hepatic and placental microsomes.,, 2011, 82,, 295-303,","journal-title":"Biochem Pharmacol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","volume":"81","author":"Lau Y.Y.","year":"2007","unstructured":"Lau YY, Huang Y, Frassetto L, Benet LZ. Clin Pharmacol Ther, Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.,, 2007, 81,, 194-204,","journal-title":"Clin Pharmacol Ther"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","volume":"35","author":"Treiber A.","year":"2007","unstructured":"Treiber A, Schneiter R, Hausler S, Stieger B. Drug Metab Dispos, Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.,, 2007, 35,, 1400-1407,","journal-title":"Drug Metab Dispos"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","volume":"40","author":"Annaert P.","year":"2010","unstructured":"Annaert P, Ye ZW, Stieger B, Augustijns P. Xenobiotica, Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.,, 2010, 40,, 163-176,","journal-title":"Xenobiotica"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0005-2736(99)00005-X","volume":"1417","author":"Okuda M.","year":"1999","unstructured":"Okuda M, Urakami Y, Saito H, Inui K. Biochim Biophys Acta, Molecular mechanisms of organic cation transport in OCT2-expressing xenopus oocytes.,, 1999, 1417,, 224-231,","journal-title":"Biochim Biophys Acta"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.V113383","volume":"11","author":"Ho E.S.","year":"2000","unstructured":"Ho ES, Lin DC, Mendel DB, Cihlar T. J Am Soc Nephrol, Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.,, 2000, 11,, 383-393,","journal-title":"J Am Soc Nephrol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.106.116517","volume":"321","author":"Chu X.Y.","year":"2007","unstructured":"Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC. J Pharmacol Exp Ther, Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance p-glycoprotein.,, 2007, 321,, 673-683,","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0022-3565(24)38862-7","volume":"295","author":"Mulato A.S.","year":"2000","unstructured":"Mulato AS, Ho ES, Cihlar T. J Pharmacol Exp Ther, Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.,, 2000, 295,, 10-15,","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2125.2007.02866.x","volume":"64","author":"Turpeinen M.","year":"2007","unstructured":"Turpeinen M, Koivuviita N, Tolonen A, Reponen P, Lundgren S, Miettunen J, Mets\u00e4rinne K, Rane A, Pelkonen O, Laine K. Br J Clin Pharmacol, Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.,, 2007, 64,, 165-173,","journal-title":"Br J Clin Pharmacol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjp.0704785","volume":"136","author":"Hayer-Zillgen M.","year":"2002","unstructured":"Hayer-Zillgen M, Br\u00fcss M, B\u00f6nisch H. Br J Pharmacol, Expression and pharmacological profile of the human organic cation transporters HOCT1, HOCT2 and HOCT3.,, 2002, 136,, 829-836,","journal-title":"Br J Pharmacol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1021\/jm8003152","volume":"51","author":"Ahlin G.","year":"2008","unstructured":"Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergstr\u00f6m CAS, Artursson P. J Med Chem, Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,, 2008, 51,, 5932-5942,","journal-title":"J Med Chem"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.109.028654","volume":"37","author":"Ahlin G.","year":"2009","unstructured":"Ahlin G, Hilgendorf C, Karlsson J, Szigyarto CAK, Uhl\u00e9n M, Artursson P. Drug Metab Dispos, Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs.,, 2009, 37,, 2275-2283,","journal-title":"Drug Metab Dispos"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mrrev.2017.05.002","volume":"773","author":"Stepanenko A.A.","year":"2017","unstructured":"Stepanenko AA, Heng HH. Mutat Res Mutat Res, Transient and stable vector transfection: pitfalls, off-target effects, artifacts.,, 2017, 773,, 91-103,","journal-title":"Mutat Res Mutat Res"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","volume":"55","author":"Karlgren M.","year":"2012","unstructured":"Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P. J Med Chem, Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): Influence of protein expression on drug-drug interactions.,, 2012, 55,, 4740-4763,","journal-title":"J Med Chem"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1023\/A:1013077609227","volume":"18","author":"Tamai I.","year":"2001","unstructured":"Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Pharm Res, Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C.,, 2001, 18,, 1262-1269,","journal-title":"Pharm Res"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/dmd.106.012930","volume":"35","author":"Noe J.","year":"2007","unstructured":"Noe J, Portmann R, Brun ME, Funk C. Drug Metab Dispos, Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.,, 2007, 35,, 1308-1314,","journal-title":"Drug Metab Dispos"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1124\/dmd.106.009530","volume":"34","author":"Sai Y.","year":"2006","unstructured":"Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. Drug Metab Dispos, Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal caco-2 cells.,, 2006, 34,, 1423-1431,","journal-title":"Drug Metab Dispos"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/aps.2014.104","volume":"36","author":"Li X.","year":"2015","unstructured":"Li X, Guo Z, Wang Y, Chen X, Liu J, Zhong D. Acta Pharmacol Sin, Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.,, 2015, 36,, 268-280,","journal-title":"Acta Pharmacol Sin"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"Kalliokoski A.","year":"2009","unstructured":"Kalliokoski A, Niemi M. Br J Pharmacol, Impact of OATP transporters on pharmacokinetics.,, 2009, 158,, 693-705,","journal-title":"Br J Pharmacol"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/dmd.118.081083","volume":"46","author":"Yang X.","year":"2018","unstructured":"Yang X, Hua W, Ryu S, Yates P, Chang C, Zhang H, Di L. Drug Metab Dispos, 11 \u03b2 -hydroxysteroid dehydrogenase 1 human tissue distribution, selective inhibitor, and role in doxorubicin metabolism.,, 2018, 46,, 1023-1029,","journal-title":"Drug Metab Dispos"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/bdd.1890","volume":"35","author":"He J.","year":"2014","unstructured":"He J, Yu Y, Prasad B, Chen X, Unadkat JD. Biopharm Drug Dispos, Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction.,, 2014, 35,, 253-263,","journal-title":"Biopharm Drug Dispos"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bcp.2010.06.025","volume":"80","author":"Hemauer S.J.","year":"2010","unstructured":"Hemauer SJ, Patrikeeva SL, Wang X, Abdelrahman DR, Hankins GDV, Ahmed MS, Nanovskaya TN. Biochem Pharmacol, Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, oh-bupropion.,, 2010, 80,, 1080-1086,","journal-title":"Biochem Pharmacol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/14767050903168424","volume":"23","author":"Earhart A.D.","year":"2010","unstructured":"Earhart AD, Patrikeeva S, Wang X, Abdelrahman DR, Hankins GDV, Ahmed MS, Nanovskaya T. J Matern Fetal Neonatal Med, Transplacental transfer and metabolism of bupropion.,, 2010, 23,, 409-416,","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1289\/ehp.0901575","volume":"118","author":"Nishikawa M.","year":"2010","unstructured":"Nishikawa M, Iwano H, Yanagisawa R, Koike N, Inoue H, Yokota H. Environ Health Perspect, Placental transfer of conjugated bisphenol a and subsequent reactivation in the rat fetus.,, 2010, 118,, 1196-1203,","journal-title":"Environ Health Perspect"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1124\/dmd.116.072363","volume":"44","author":"Sager J.E.","year":"2016","unstructured":"Sager JE, Price LSL, Isoherranen N. Drug Metab Dispos, stereoselective metabolism of bupropion to OH-bupropion, threohydrobupropion, erythrohydrobupropion, and 4\u2032-OH-bupropion in vitro.,, 2016, 44,, 1709-1719,","journal-title":"Drug Metab Dispos"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/03602532.2014.887094","volume":"46","author":"Zhou Q.","year":"2014","unstructured":"Zhou Q, Yu LS, Zeng S. Drug Metab Rev, Stereoselectivity of chiral drug transport: a focus on enantiomer-transporter interaction.,, 2014, 46,, 283-290,","journal-title":"Drug Metab Rev"}],"container-title":["Drug Metabolism Letters"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/167844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:10:05Z","timestamp":1775286605000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/167844\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,4,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872312813666181129101507","relation":{},"ISSN":["1872-3128"],"issn-type":[{"value":"1872-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}